Combined Effect of Therapeutic Ultrasound and Trans Cutaneous Electrical Nerve Stimulation on Endometriosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Medical treatment, Therapeutic ultrasound (US), Transcutaneous electrical nerve stimulation (TENS).
- Who it may be relevant to
- Registry conditions: Endometriosis. Basic parameters: 25 years — 35 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study will be conducted to investigate the combined effect of therapeutic ultrasound and transcutaneous electrical nerve stimulation (TENS) on relieving adhesions and pain related to endometriosis.
Detailed description
Endometriosis affects 10-15% of reproductive-age women, causing pelvic pain and infertility. While laparoscopy is the primary treatment, it has risks. Medications are also used but often have side effects. Complementary therapies like acupuncture, yoga, and physical therapy modalities show promise. Therapeutic ultrasound has demonstrated effectiveness in managing chronic pain and adhesions associated with endometriosis. Transcutaneous electrical nerve stimulation (TENS) has shown positive results in pain relief and potentially improving uterine conditions for implantation. This study aims to investigate the combined effect of therapeutic ultrasound and TENS on endometriosis-related adhesion and pain, providing valuable information for physical therapists in treating this condition.
Interventions
- Drug Medical treatment
All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist. - Device Therapeutic ultrasound (US)
Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel. - Device Transcutaneous electrical nerve stimulation (TENS)
TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
Primary outcome measures
- Assessment of adhesion size [Time frame: 8 weeks]
- The McGill pain questionnaire (MPQ) [Time frame: 8 weeks]
- The Endometriosis Health profile (EHP30) questionnaire [Time frame: 8 weeks]
Secondary outcome measures (1)
- The Health-related quality of life (HRQOL-36) questionnaire [Time frame: 8 weeks]
Eligibility criteria
Inclusion criteria
- Forty-five women clinically diagnosed by the gynecologist with endometriosis will be included in the study.
- Abdominal wall endometriosis will be diagnosed via Color Doppler ultrasonography.
- Their ages will range from 25 to 35 years old.
- Their body mass index (BMI) will be ranged from 25 to 35 Kg/m2.
- All patients have reported mild to moderate endometriosis symptoms such as (chronic pelvic pain (CPP), dysmenorrhea, dyspareunia, pain with bowel movements and urination and excessive bleeding) as recorded by Endometriosis Health profile questionnaire (EHP30).
- All patients use continuous hormonal treatment for at least 3 months.
Exclusion criteria
- Severe endometriosis which is diagnosed by the gynecologist.
- Pregnancy, peacemaker, epilepsy, cardiac arrhythmia, cancer, acute inflammatory pelvic disease.
- Use of injectable hormonal therapy within the previous 6 weeks.
- Patients with contraindication of ultrasound (Patients with reduced sensation to pain and/or heat, local malignancy, local acute infection and over areas of thrombosis or other vascular abnormalities).
- Cognitive deficiency and difficulty to understand instructions or use the instruments.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06537765 · 012/003874